Abstracts tagged "Reactive arthritis"

Abstract Number: 1673 • ACR Convergence 2025
Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study
Anirudh Bandu¹, Michal Cidon² and Michael Weisman³, ¹CHLA, Los Angeles, NJ, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³Cedars-Sinai Medical Center, LOS ANGELES, CA
Background/Purpose: Transient synovitis (TS) of the hip is considered a common, self-limited condition in the pediatric population. However, recurrences can occur; these may signal an…
Abstract Number: 1614 • ACR Convergence 2025
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
Alice Bartoletti¹, Georgina Ducker², Mrinalini Dey³, Durga Prasanna Misra⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Department of Rheumatology, ASST Gaetano Pini CTO, Milan, Italy, Milan, Lombardia, Italy, ²Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ³Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK, London, England, United Kingdom, ⁴Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) date back to 2015…
Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…
Abstract Number: 1161 • ACR Convergence 2025
Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases
Javier Narváez¹, Orfa Barrios², Pol Maymó-Paituvi³, JUAN JOSE ALEGRE SANCHO⁴, Ivan Castellví⁵, Vanesa Vicens Zygmunt⁶, Guadalupe Bermudo⁷, Laia De Daniel Bisbe³, Martí Aguilar-Coll⁸, Montserrat Roig Kim³, Joan Miquel Nolla³ and Maria Molina-Molina⁷, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology. Hospital Nacional Arzobispo Loayza, Lima, Peru, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ⁶Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁸Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To evaluate the efficacy, safety, and tolerability of the antifibrotic agents nintedanib and pirfenidone in the treatment of interstitial lung disease (ILD) associated with…
Abstract Number: 0533 • ACR Convergence 2025
Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
Avarna Agarwal¹, Phanidhar Dhanekula¹, Sarthak Verma¹, Subham ravi Nayak², Prakashini Mruthyanjaya¹, Prasanta Padhan¹, A Rajkumar Patro², Ramnath Misra¹ and Sakir Ahmed¹, ¹Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India, ²Department of Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, Orissa, India
Background/Purpose: In reactive arthritis (ReA) approximately a half of patients achieve drug-free remission (DFR), while others develop chronic disease. To identify predictive biomarkers for DFR,…
Abstract Number: 0429 • ACR Convergence 2025
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Xuemei Tang¹, Xiwen Luo², Xiya Luo¹, Mengwei Ding³, Xi Yang², Dawei Liu², Li Xu², Zhiyong Zhang², Yunfei An² and Xiaodong Zhao¹, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ³Big Data Center for Children’s Medical Care, Children’s Hospital of Chongqing Medical University, Chongqing, China., Chongqing, China (People's Republic)
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…
Abstract Number: 2189 • ACR Convergence 2024
Migratory Arthritis in Children: What Besides Rheumatic Fever?
bar goldberg¹, Gil Amarilyo², oded Scheuerman¹, tarek Zuabi³, alina Guz¹, Maayan Ravia¹ and yoel Levinsky¹, ¹schneider medical center, petah tikva, Israel, ²Faculty of Medicine, Tel Aviv University, Tel Aviv; Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, Kibbutz Maggal, HaMerkaz, Israel, ³schneider medical center, petah tikva
Background/Purpose: Migratory Arthritis, a not uncommon presentation in pediatrics, is classically associated with rheumatic fever (RF), although can be the first presentation of other medical…
Abstract Number: 1785 • ACR Convergence 2023
Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis
Prakashini MV¹, Soumendu Mahapatra², Krushna Chandra Murmu², Rasmita Mishra², Prasanta Padhan¹, Punit Prasad², Ramnath Misra³ and Sakir Ahmed⁴, ¹Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India, ²Institute of Life Sciences, Bhubaneswar, India, ³Kalinga Institute of Medical Sciences, KIIT University, Lucknow, India, ⁴Kalinga Institute of Medical Sciences, Bhubaneswar, India
Background/Purpose: Reactive arthritis (ReA) is the unique infection-triggered spondyloarthritis (SpA). Undifferentiated peripheral SpA (UpSpA) is similar but without previous infection, or psoriasis or inflammatory bowel…
Abstract Number: 0274 • ACR Convergence 2022
Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset
Sabina Ciciriello¹, Geoffrey Littlejohn², Tamas Treuer³, Kathryn Gibson⁴, Peter Youssef⁵, Paul Bird⁶, Catherine OSullivan⁷, Tegan Smith⁸ and Claire Deakin⁹, ¹Melbourne Health, Melbourne, Australia, ²OPAL Rheumatology Ltd, Melbourne, Australia, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, United States of America, Sydney, Australia, ⁵University of Sydney, Sydney, Australia, ⁶University of New South Wales, Sydney, Australia, ⁷OPAL Rheumatology Ltd, Sydney, Australia, ⁸OPAL Rheumatology Ltd, Geelong, Australia, ⁹OPAL Rheumatology Ltd, Mosman, Australia
Background/Purpose: JAK inhibitors (JAKi) have been a major development in treatment for many patients with RA due to their ability to block multiple cytokine pathways…
Abstract Number: 0772 • ACR Convergence 2022
New Onset Rheumatologic Syndromes After Covid-19 Vaccination: Systematic Review
Carina Soto-Fajardo¹, Angélica Peña Ayala², Fernanda Gonzalez², Paola Flores², Ana Cristina Medina², Araceli Bernal², Carlos Pineda², Olga-Lidia Vera-Lastra³ and Luis Javier Jara Quezada², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Centro Médico La Raza, Ciudad de México, Mexico
Background/Purpose: From January 2021 around 60% of the total population has received at least one dose of any COVID-19 vaccine. A minority of vaccinated individuals…
Abstract Number: 2246 • ACR Convergence 2022
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…
Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Sophie Wojcik¹, Davina Morris², Gillian Fitzgerald³, Steve Ramkissoon⁴, Nigil Haroon² and Robert Inman⁵, ¹UHN, Montreal, QC, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…
Abstract Number: 12 • 2019 ACR/ARP Annual Meeting
Intraarticular and Circulatory Cytokine Responses to Chlamydia Trachomatis: A Clinical Study in Reactive Arthritis/ Undifferentiated Spondyloarthropathy Patients
Sangita Rastogi¹, Praveen Kumar ², Darshan Bhakuni ³ and Geetika Khanna ⁴, ¹ICMR- National Institute of Pathology, Safdarjung hospital campus, New Delhi- 110 029, India, New Delhi, Delhi, India, ²ICMR- National Institute of Pathology, Safdarjung hospital campus, New Delhi- 110 029, India, Kota, Rajasthan, India, ³Department of Rheumatology and Clinical Immunology, Army Hospital (Research & Referral), Dhaula Kuan, New Delhi- 110 010, India, New Delhi, Delhi, India, ⁴Central Institute of Orthopedics (CIO), Vardhaman Mahavir Medical College (VMMC) & Safdarjung hospital, New Delhi-110029, India, New Delhi, Delhi, India
Background/Purpose: Chlamydia trachomatis-induced reactive arthritis (ReA)/ undifferentiated spondyloarthropathy (uSpA) is an immune-mediated situation where development of disease and maintenance of this pathogen remains elusive. The…
Abstract Number: 271 • 2017 ACR/ARHP Annual Meeting
The Trend of Incidence Rate, Frequency and HLA Phenotype of Reactive Arthritis and Uveitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20-Year, Two-Center Retrospective Study
Yoshinori Taniguchi¹, Satoshi Inotani², Hirofumi Nishikawa², Kosuke Inoue³, Taro Horino², Takashi Karashima⁴, Yasuhiko Yoshinaga⁵ and Yoshio Terada³, ¹Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ²Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ³Kochi University, Nankoku, Japan, ⁴Urology, Kochi University, Nankoku, Japan, ⁵Kurashiki Medical Center, Kurashiki, Japan
Background/Purpose: Intravesical instillation of Bacillus Calmette-Guerin (iBCG) is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive…
Abstract Number: 1312 • 2016 ACR/ARHP Annual Meeting
Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study
Satoshi Inotani^1,2,3,4, Yoshinori Taniguchi⁵, Takashi Karashima⁶, Yasuhiko Yoshinaga⁷, Hirofumi Nishikawa⁸, Natsuki Maeda⁹, Shimpei Fujimoto⁸ and Yoshio Terada¹⁰, ¹internal medicine, Chikamori Hospital, Kochi, Japan, ²Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi medical school, Nankoku, Japan, ³Urology, Kochi medical school, Nankoku, Japan, ⁴Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ⁵Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ⁶Urology, Kochi University, Nankoku, Japan, ⁷Kurashiki Medical Center, Kurashiki, Japan, ⁸Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ⁹Endocrinology,Metabolism,Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ¹⁰Kochi University, Nankoku, Japan
Background/Purpose: To evaluate the incidence of reactive arthritis (ReA), uveitis and conjunctivitis in Japanese patients with bladder cancer following intravesical BCG therapy (iBCG). Methods: The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].